Market Signal Briefing

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

New York, New York--(Newsfile Corp. - February 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period"), of the important March 16, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Vistagen class action, go to https://rosenlegal.com/submit-form/?case_id=50827 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning Vistagen's plan to develop and commercialize its drug fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD). Defendants' statements included, among other things, Vistagen's positive assertions of fasedienol's future trial success based on the prior positive results associated with the PALISADE-2 clinical trial, in addition to notable enhancements and operational changes made to the execution of the PALISADE-3 clinical trial supported a strong likelihood of Phase 3 success and positioned it as a confirmatory study.

According to the lawsuit, defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Vistagen class action, go to https://rosenlegal.com/submit-form/?case_id=50827 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283162

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

In brief CoinShares said quantum computing poses a theoretical risk to Bitcoin, but not an imminent one. Researchers estimate millions of qubits would be needed, far beyond today’s quantum machines. The firm also said any future response should favor gradual upgrades over aggressive protocol changes. Quantum computing may not be as much of an immediate threat to Bitcoin as some have warned, and any real risk might still be years away.

That’s according to a new research note from digital asset investment firm CoinShares, which argues that while Bitcoin’s cryptography is theoretically vulnerable to future quantum advances, current technology falls far short of posing a practical danger.

“Bitcoin’s quantum vulnerability is not an immediate crisis but a foreseeable engineering consideration, with ample time for adaptation,​“ researchers at the firm wrote.

Quantum attacks involve powerful quantum computers breaking cryptographic keys that secure Bitcoin or other blockchains, enabling attackers to derive private keys from public information.

Such attacks that are aimed at Bitcoin are not imminent because breaking its core cryptography would require quantum machines far beyond anything that exists today, the researchers argue.

Estimates cited by CoinShares suggest an attacker would need millions of qubits, which are orders of magnitude more than current systems, to crack a key within hours or days.

Researchers estimate that even the most advanced quantum computers are 10 to 100,000 times too weak to pose a real-world threat, pushing meaningful risk into the 2030s or later.

Still, legacy addresses could be vulnerable over long timeframes, while attacking active transactions would require near-instant computations that remain far out of reach.

CoinShares said the theoretical quantum risk to Bitcoin stems from algorithms that could eventually expose cryptographic keys or weaken hashing, but stressed that these threats are distant and narrowly scoped.

The firm estimates that about 1.7 million BTC, or roughly 8% of supply, sit in legacy P2PK addresses with exposed public keys, while modern address types hide keys until coins are spent and cannot affect Bitcoin’s supply cap or proof-of-work.

Even in an extreme scenario, CoinShares argued the market impact would be limited, with at most around 10,000 BTC realistically able to be compromised and sold suddenly.

More aggressive fixes could secure the network earlier, but the firm warns they also carry risks, including software bugs, forced assumptions about dormant coins, and erosion of Bitcoin’s neutrality and trust, making gradual, voluntary migration the preferred path.

The takeaway appears to be all about process. CoinShares said in its note that Bitcoin has clear upgrade paths if quantum threats materialize, allowing the network to adapt without disruption, and that the risk should be weighed against fundamentals rather than speculative worst-case scenarios.

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

Japanese mandate sparks surge in equities and safe havens. Feb 9, 2026, 1:18 a.m.

Japan’s Nikkei 225 surged to a record on Monday, breaching the 57,000 level with a 3.4% gain following Prime Minister Sanae Takaichi’s decisive "supermajority" victory in the Sunday general election, according to Nikkei Asia.

This political mandate signaled a green light for Takaichi’s aggressive expansionary fiscal agenda, which includes a massive $135 billion stimulus package aimed at revitalizing the economy through infrastructure spending and tax cuts.

STORY CONTINUES BELOW

The "Takaichi Trade" sparked a global ripple effect, driving gold prices past the $5,000 per ounce milestone and pushing bitcoin to a brief peak of $72,000, before settling back above $70,000 during Asia morning trading hours. U.S. stock market futures opened higher.

The market euphoria was further bolstered by international support, with both President Donald Trump and U.S. Treasury Secretary Scott Bessent congratulating the Prime Minister.

Trump is eyeing 100,000 on the Dow Jones (DJI) by the end of his term, a 100% increase from current levels. The DJI on Friday breached 50,000 for the first time.

Institutional demand for onchain yield is accelerating as Evernorth moves to tap native XRP credit markets, signaling a potential evolution in how large holders deploy liquidity, earn yield, and reshape XRP Ledger finance.

By PYMNTS  |  February 8, 2026

 | 

A South Korean cryptocurrency exchange is facing regulatory investigation following a $40 billion bitcoin-related mistake.

That exchange, Bithumb, announced this weekend it had accidentally given out $40 billion in the world’s most popular crypto to customers as part of a promotional rewards program. The company said it has since recovered nearly all the coins in question. 

A report on the incident by Reuters said the company had planned to distribute small cash rewards of 2,000 Korean won ($1.40) or more to each user as part of the promotion, but winners received at least 2,000 bitcoins each instead.

“We would like to make it clear that this incident is unrelated to external hacking or security breaches, and there are no problems with system security or customer asset management,” Bithumb said in a statement.

However, financial regulators in South Korea said the incident has exposed the vulnerabilities and risks of virtual assets, the Reuters report added.

Regulators say they will conduct an on-site inspection of Bithumb and other crypto exchanges if irregularities are discovered in reviews of their internal control systems, along with their holdings and operations of virtual assets, the report said.

Advertisement: Scroll to Continue

In other crypto news, PYMNTS looked at the state of the market amid the massive drop in the price of bitcoin, which fell to $70,000 in recent days after hitting a record high of more than $126,000 in October of 2025. The coin is now at its lowest point since November 2024. 

And what is important here isn’t just bitcoin’s decline, but “how balance sheets, equity markets and forced behavior” interact when that happens, PYMNTS wrote.

“Companies whose valuation narratives are explicitly tied to bitcoin, most famously Michael Saylor’s Strategy and its cadre of copycat crypto treasury businesses, all function like leveraged bitcoin ETFs, even if they’re not structured that way,” that report added. “When bitcoin drops 10%, the stock might drop 25% or 40%. That volatility doesn’t stay isolated; it can spill into broader risk sentiment, especially for tech and speculative growth names.”

The report also cited a note from investor Michael Burry which points out that close to 200 publicly traded companies now hold significant amounts of bitcoin. 

“If prices fall further, risk managers and boards will begin recommending sales not for strategic reasons, but to protect capital and satisfy risk policies,” PYMNTS wrote. “Those sales, broadcast through financial reporting, can create downward pressure on price.”

Active Currencies 18945

Market Cap $2,460,600,094,961.40

Bitcoin Share 57.14%

24h Market Cap Change $0.47

AMBCrypto

Ethereum hits 15.19M users, but where does leverage stand now?

Journalist

Posted: February 9, 2026

Ethereum [ETH] network activity is picking up pace. At the same time, market positioning feels far less settled. Especially since sentiment is swinging so quickly right now!

This split between what’s happening on-chain and how traders are behaving makes things interesting for ETH.

Activity at a record high

Samyukhtha L KM is a Financial Journalist and Market Analyst at AMBCrypto whose work is defined by one central question: Is the latest trend in blockchain hype, or history in the making? Her expertise is built on a strong academic foundation, with a Master’s in Journalism and Mass Communication from Amity University and a Bachelor’s in Commerce from the University of Madras. This dual qualification equips her with a unique skill set: the financial acumen to dissect market mechanics and the journalistic rigor to investigate and communicate complex subjects with clarity. Samyukhtha specializes in analyzing the socio-economic impact of blockchain adoption and assessing the viability of new market narratives. This includes a focus on high-velocity, community-driven assets such as memecoins, where she evaluates sentiment and fundamentals. She is dedicated to providing readers with insightful, well-researched commentary that looks beyond immediate market moves to understand the long-term implications of decentralized technology.

TLDR: MegaETH launched with Chainlink integration, enabling immediate access to $14B in DeFi assets and protocols.  Chainlink’s oracle infrastructure powers 70% of DeFi markets with over $27 trillion in transaction value.  CCIP enables cross-chain liquidity for Lombard and Lido assets across MegaETH and other blockchain networks.  Aave and GMX protocols are now available on MegaETH through Chainlink’s data and interoperability standards.
MegaETH has joined the Chainlink Scale program and integrated Chainlink’s data and interoperability infrastructure at launch.

The collaboration provides immediate access to leading DeFi protocols, including Aave and GMX. Users can now interact with nearly $14 billion in flagship assets such as Lido’s wstETH and Lombard’s BTC.b and LBTC.

The integration went live on Monday, marking a strategic partnership between the real-time blockchain platform and the oracle network.

Chainlink Infrastructure Powers MegaETH’s DeFi Ecosystem The integration brings Chainlink Data Feeds, Data Streams, and Cross-Chain Interoperability Protocol (CCIP) to MegaETH. These services enable developers to build high-performance decentralized applications on the platform.

The oracle infrastructure has facilitated over $27 trillion in onchain transaction value across the industry. Currently, Chainlink powers approximately 70% of existing DeFi markets globally.

MegaETH users gain access to multiple DeFi protocols through this partnership. Aave and GMX are among the prominent platforms now available on the network.

Additionally, HelloTrade and Avon have joined the ecosystem at launch. The integration creates opportunities for lending protocols, derivatives markets, and decentralized exchanges to operate efficiently.

The platform features a custom integration designed to deliver fast market data. This setup supports MegaETH’s objective of becoming the first real-time blockchain.

Developers can now build applications requiring accurate price feeds and reliable data sources. The infrastructure ensures consistency across various financial products and services.

CCIP enables secure cross-chain asset transfers for MegaETH users. Asset issuers like Lombard and Lido can provide liquidity across multiple blockchain networks.

The protocol offers compliance-enabled interoperability for developers building composable applications. This functionality extends MegaETH’s reach beyond its native ecosystem into broader multi-chain environments.

Scale Program Benefits and Industry Adoption The Chainlink Scale program provides MegaETH developers with low-cost oracle services. Institutions building on the platform receive access to secure data infrastructure from day one.

Oracle nodes supply trusted information to support both traditional and decentralized finance applications. The program reduces barriers for teams developing on MegaETH.

Johann Eid, Chief Business Officer at Chainlink Labs, commented on the partnership’s scope. “MegaETH joining Chainlink Scale and adopting the Chainlink data and interoperability standards is a major moment for our ecosystem,” Eid stated.

He added that the infrastructure has enabled tens of trillions in onchain transaction value. The integration brings users access to protocols like Aave and GMX alongside key DeFi assets.

Stani Kulechov, Founder of Aave Labs, addressed the upcoming Aave launch on MegaETH. “The upcoming Aave launch on MegaETH with Chainlink live from day one will give users access to the high-quality data,” Kulechov explained.

He noted that Chainlink’s standards have been foundational to Aave’s multi-ecosystem growth. The integration enables seamless extension onto MegaETH’s next-generation blockchain platform.

Lei Yang, Co-Founder and CTO of MegaETH, outlined the strategic rationale behind joining Chainlink Scale. “Joining Chainlink Scale ensures that our developers have access to high-quality data and secure interoperability,” Yang said.

He emphasized the importance of providing developers with necessary tools from day one. The partnership supports MegaETH’s goal of becoming the leading blockchain platform in the industry.

Kyle Samani, co-founder of Multicoin Capital and one of the crypto industry’s most influential Solana advocates, officially stepped down from the firm on February 5, 2026, after nearly a decade at the helm. Just days later, his public criticism of Hyperliquid (HYPE) has ignited speculation, especially as on-chain data indicates wallets linked to Multicoin accumulated more than $40 million worth of HYPE tokens in late January.

The timing has drawn intense scrutiny across crypto markets. While Samani stated upon departure that he would remain active in the crypto space, particularly within the Solana ecosystem, his sharp comments about Hyperliquid marked a clear ideological stance. In a widely shared social media post, Samani described Hyperliquid as “everything wrong with crypto,” criticizing its closed-source design, permissioned structure, and alleged regulatory and ethical concerns. These remarks stand in stark contrast to Multicoin’s apparent exposure to the HYPE token.

Blockchain analysts previously flagged significant ETH flows moving through intermediary wallets and ultimately rotating into HYPE over several days. Although no official confirmation has tied these purchases directly to Multicoin’s internal strategy, market observers quickly connected the dots, questioning whether internal disagreements over investment direction contributed to Samani’s exit.

Multicoin Capital has long been associated with a strong Solana-focused thesis. The firm championed transparent, yield-driven models through staking, DeFi, and capital-efficient infrastructure. Its major investments, including a $1.65 billion Solana treasury initiative with Forward Industries, reinforced this philosophy, emphasizing decentralization, open systems, and native blockchain yields.

Hyperliquid, by contrast, operates a high-performance decentralized perpetual futures exchange with its own blockchain, prioritizing speed, liquidity, and leverage. Critics point to its centralized validator model and closed-source code as fundamental trade-offs, while supporters argue that its revenue-sharing and token buyback mechanisms better align users with the platform.

Neither Multicoin nor Samani has publicly linked his departure to Hyperliquid or any specific portfolio decision. Still, the convergence of on-chain transparency, leadership change, and outspoken criticism has fueled an ongoing ideological debate within crypto. As HYPE’s price action shows signs of recovery, the episode highlights the broader tension between decentralization ideals and performance-driven infrastructure that continues to shape the digital asset industry.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

After weeks of sustained selling pressure, XRP has staged a notable short-term recovery, drawing renewed attention from traders and investors across major cryptocurrency exchanges. Recent market data shows that nearly $991 million in bounce-related trading volume flowed through leading platforms such as Binance, signaling a temporary return of risk appetite in the XRP market.

Prior to this rebound, XRP had been locked in a clear downward channel. Sellers consistently dominated price action, repeatedly pushing the asset lower whenever it attempted to reclaim key moving averages. Each rally over the past several weeks was quickly sold into, gradually driving XRP toward oversold conditions and weakening confidence among both institutional and retail participants.

The latest price action, however, suggests a shift in short-term dynamics. Buyers have begun aggressively accumulating XRP near established support levels, triggering a sharp reaction move to the upside. The accompanying surge in trading volume is particularly important, as recoveries without strong volume often fail to gain traction. The near-billion-dollar spike indicates that significant capital entered the market to absorb selling pressure rather than relying on short-covering alone.

As a result of this move, XRP has managed to reclaim several short-term levels that previously acted as breakdown points. This recovery has given traders an opportunity to reassess positioning and short-term strategies. Momentum indicators are also beginning to reflect easing downside pressure. The relative strength index, which had been deeply oversold, is now turning upward, a common signal that selling momentum is weakening and that a corrective bounce may continue.

Additional support for the move comes from futures and spot market data, which point to renewed buying interest rather than a purely technical rebound. Still, caution remains warranted. Weekend trading often comes with thinner liquidity, which can exaggerate price swings. When full market participation resumes at the start of the week, XRP will face a critical test. A renewed wave of selling pressure could quickly erase recent gains and push the price back toward recent lows if buyers fail to maintain momentum.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Robert Kiyosaki pushes back against critics questioning his bitcoin buying claims, framing the dispute around price conviction over timing as his past posts reveal a pattern of purchasing during major market rallies.

Campaign debuted during Super Bowl LX and introduced www.NextInMS.com, a new platform designed to create space for honest conversation among people living with MS February 08, 2026 16:17 ET  | Source: TG Therapeutics, Inc.

A Media Snippet accompanying this announcement is available by clicking on this link.

NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced a collaboration with actress Christina Applegate to help raise awareness of multiple sclerosis (MS) and support meaningful conversations for those living with the disease.

Christina Applegate, who has been living with MS for 5 years, will lead the new national disease-awareness initiative designed to elevate the voices of people living with MS, highlight the realities, and explore what comes next, on their own terms.

The cornerstone of the campaign is www.NextInMS.com, a new platform developed to support people living with MS. Through Next In MSTM, Christina extends the same unfiltered honesty she has brought to her own experience into shared conversations with others living with MS. The platform will feature exclusive content including Christina’s personal perspectives on navigating life with MS, long-term decision-making, engaging with the healthcare system, and prioritizing quality of life while living with a chronic condition. It is expected to also include educational content from leading MS experts offering current insights on topics of interest to the MS community. Together, these efforts are intended to foster open, informed dialogue among people living with MS, caregivers, and healthcare professionals.

“MS isn’t something you neatly figure out and move on from — it’s messy, it’s unpredictable and some days it frankly just sucks,” said Christina Applegate. “I’ve always tried to be honest about that. Next In MS is about opening up those conversations, expanding our understanding and always being prepared for what’s next. I’m excited to be partnering with TG Therapeutics, and together hopefully we can reach more members of the MS community, cut through the noise and talk openly about the truths of living with MS — the challenging ones and the hopeful ones too.”

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, added, “Christina brings a level of openness and authenticity that resonates deeply with us at TG. We’re honored to collaborate with her as she shares her perspective and as we collectively look toward what’s next in MS. At TG Therapeutics, we remain committed to advancing innovation and supporting efforts that keep those living with MS at the center of everything we do.”

TG’s focus on advancing innovation in multiple sclerosis includes not only the development of novel therapies, but also a commitment to supporting resources that help people living with MS feel informed and empowered throughout their care journey.

ABOUT WWW.NEXTINMS.COM
Next In MSTM is a platform designed to create space for people living with MS to have honest conversations about their experience and explore together what comes next, on their own terms. The platform centers on real, unfiltered dialogue, including conversations between Christina Applegate and others living with MS, and reflects the everyday realities, questions, and decisions that shape life with the disease. Next In MS is intended to support people living with MS in carrying that openness beyond the platform, into conversations with family members, friends, and healthcare professionals, when and how they choose. The platform is designed to evolve over time as those conversations continue.

ABOUT TG THERAPEUTICS 
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has a product approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, and by several regulatory agencies outside of the U.S to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit

www.tgtherapeutics.com, and follow us on X

@TGTherapeutics and on

LinkedIn.

Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. All statements contained in this press release other than statements of historical facts, including statements regarding our collaboration with Christina Applegate, and the www.nextinms.com platform may constitute forward-looking statements. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release.

Additional factors that could cause our actual results to differ materially include the following: the Company’s ability to continue to commercialize their marketed product; the risk that the collaboration with Christina Applegate, does not go as planned; the risk that the www.nextinms.com platform does not gain traction or ceases to exist; the risk that due to regulatory enforcement or other reasons any portion of the collaboration described today is not able to be implemented; the risk that the Company does not achieve its 2026 development pipeline anticipated milestones or goals in the timeframe projected or at all; the uncertainties generally inherent in research and development; regulatory developments, legislative actions, executive orders, including the imposition of tariffs and policy changes in the U.S. and other jurisdictions; and general political, economic and business conditions. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our other filings with the Securities and Exchange Commission.

Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

CONTACT:

Investor Relations
Email:[email protected]
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations
Email:[email protected]
Telephone: 1.877.575.TGTX (8489), Option 6

1. MS Prevalence. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Data monitor p. 236.

Expense ratios, dividend yields, and sector focus set these consumer staples ETFs apart — see how their strategies impact investor portfolios.

The Vanguard Consumer Staples ETF (VDC +1.35%) stands out for its low cost and broad sector coverage, while the First Trust Nasdaq Food & Beverage ETF (FTXG +1.16%) trades at a higher expense, pays a higher yield, and zeroes in on food and beverage companies.

Both funds target the consumer staples space, but VDC casts a wider net across non-discretionary products, whereas FTXG focuses specifically on food and beverage stocks. This comparison helps clarify if the extra yield and niche tilt in FTXG compensate for its higher costs and narrower portfolio.

Snapshot (cost & size)MetricVDCFTXGIssuerVanguardFirst TrustExpense ratio0.09%0.60%1-yr return (as of 2026-02-06)12.06%9.78%Dividend yield2.10%2.75%Beta0.640.52AUM$9.05 billion$17.89 millionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year weekly returns. The 1-yr return represents total return over the trailing 12 months.

VDC is significantly more affordable with a 0.09% expense ratio, while FTXG charges 0.60%. FTXG may appeal to those seeking a higher payout, offering a 2.75% dividend yield versus VDC’s 2.10%.

Performance & risk comparisonMetricVDCFTXGMax drawdown (5 yr)(16.55%)(21.71%)Growth of $1,000 over 5 years$1,385$925What's insideFTXG focuses on the food and beverage industry, holding just 31 stocks with 91% in consumer defensive, 7% in basic materials, and 2% in industrials. Its top holdings are PepsiCo, Inc. (PEP +1.84%), Archer-Daniels-Midland Company (ADM +1.44%), and Mondelez International, Inc. (MDLZ 0.42%). The fund has a track record of 9.4 years. No notable quirks are present.

In contrast, VDC tracks a broader consumer staples basket, with 98% in consumer defensive and 2% in consumer cyclical. Its top stocks are Walmart (WMT +3.42%), Costco Wholesale Corp. (COST +1.16%), and Procter & Gamble Co. (PG +0.45%). With 103 holdings, VDC offers greater diversification across household and personal products, not just food and beverage.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsBoth the Vanguard Consumer Staples ETF (VDC) and the First Trust Nasdaq Food & Beverage ETF (FTXG) offer investors exposure to the stable, income-generating consumer staples sector. The choice comes down to whether FTXG’s focus on the food and beverage industry or VDC’s broader consumer staples approach is preferred.

If you don’t have holdings in the consumer staples industry or are looking to expand in this area for your portfolio, VDC is the better ETF over FTXG for several reasons.

VDC has a higher one-year return, smaller max drawdown, and a lower expense ratio. It also sports substantial assets under management of over $9 billion compared to FTXG’s much smaller $17.9 million, giving VDC greater liquidity.

In addition, Vanguard’s ETF delivers much better diversification, given it contains over 100 holdings versus FTXG’s small basket of 31 stocks. This helps buoy VDC during downturns in some stocks or industry segments whereas FTXG is more vulnerable.

FTXG is the ETF for investors who want to increase their exposure specifically to the food and beverage sector, and are willing to pay a higher expense ratio for it. The fund also boasts a higher dividend yield. Outside of that, VDC is the better choice.

Three tailwinds could lift this sector when the new Fed Chair makes his mark.

President Donald Trump hasn't been shy in demanding that the Federal Reserve cut interest rates, and unsurprisingly, his choice to succeed Fed Chair Jerome Powell is potentially on the same page. Kevin Warsh has echoed the President's calls for lower rates in recent months, and federal funds traders now forecast an 81% chance of a rate cut by this summer, with a 45% chance of one in April, before Warsh is even sworn in.

After almost four years of tight monetary policy, there are indications that U.S. companies can look forward to lower borrowing costs. That's great news for real estate investment trusts (REITs), which benefit from lower interest rates in three ways.

Image source: Getty Images.

These companies, which follow tax-related rules that require them to pay 90% of their net income back to shareholders as dividends, typically offer high yields that attract income investors who might otherwise be left out in the cold by falling Treasury yields. Their valuations can also rise because their future cash flows are discounted using the 10-year Treasury yield as a benchmark, so as the latter falls, REIT valuations rise. Finally, lower borrowing costs naturally boost REITs, since they fund their long-term operations through long-duration debt that can be refinanced at more favorable terms when interest rates fall.

You can see REITs' tendency to outperform by comparing their returns during the last era of prolonged low rates against those of the S&P 500. From June 2009 to November 2015, when the federal funds rate never exceeded 0.21%, the Vanguard Real Estate Index Fund ETF (VNQ +1.57%), an exchange-traded fund (ETF) that offers broad exposure to U.S. equity REITs, handily beat the S&P 500's total return.

Data by YCharts.

Still, not all REITs will thrive amid falling rates, while others will be standout performers. Here are three opportunities in the REIT universe to consider buying now.

1. Realty Income Founded in 1969 and headquartered in Vancouver, Canada, Realty Income (O 0.17%) is the sixth-largest REIT globally, with properties in nine countries totaling $61 billion in value. Its clients include Lowe's, Chipotle, Sainsbury's, and Walmart.

Today's Change

(

-0.17

%) $

-0.11

Current Price

$

63.25

As of Q3 2025, the company has announced 112 consecutive quarterly increases to its dividend. And with earnings growing 17% year over year last quarter, this streak looks highly likely to continue. Realty Income pays a monthly dividend yielding 5.2% today, well above the S&P 500 average of 1.16%.

2. Prologis San Francisco-based Prologis (PLD +0.59%) is a REIT operating in 20 countries, with $215 billion in assets under management. Its dividend growth from 2019 to 2024 outpaced the entire REIT sector by 2-to-1, and on Feb. 20, 2025, its management approved another 5% dividend hike. This timing suggests that another dividend increase announcement could be just days away.

Today's Change

(

0.59

%) $

0.81

Current Price

$

136.95

In the meantime, the company offers a dividend yield of 3%, nearly triple the S&P 500 average. Given that it grew earnings by 9.5% year over year in the last quarter, an imminent dividend increase could be in that neighborhood.

3. Vanguard Real Estate Index Fund ETF The aforementioned Vanguard Real Estate Index Fund ETF counts 152 REIT stocks among its holdings, providing broad-based exposure to the industry. Designed to provide high income and moderate long-term capital appreciation, the fund tracks the performance of a benchmark, the MSCI U.S. Investable Market Real Estate 25/50 Index.

Its yield stands at 3.82% today, over triple the S&P 500 average. Being passively managed, it has a low expense ratio of 0.13%, compared to the industry average of 0.48%.

Today's Change

(

1.57

%) $

1.43

Current Price

$

92.25

Year to date, the fund is up just 2%, which suggests Wall Street hasn't warmed to REITs even as signs abound that lower rates are coming. Since its inception in September 2004, the ETF has averaged an annual return of 7.41%. Yet it has a history of significantly outperforming in times of low rates. It returned over 200% from June 2009 to November 2015, the last prolonged era of cheap money.

For investors seeking income and stability amid a return to low rates, these three REIT opportunities are buys.

Explore how these two consumer staples ETFs differ in cost, structure, and risk — key factors for building a resilient portfolio.

The Fidelity MSCI Consumer Staples Index ETF (FSTA +1.31%) and the Invesco S&P 500 Equal Weight Consumer Staples ETF (RSPS +1.09%) both target U.S. consumer staples stocks, but their approaches lead to distinct results.

This comparison breaks down how their fees, returns, risk, liquidity, and holdings stack up for investors looking to access this defensive sector.

Snapshot (cost & size)MetricRSPSFSTAIssuerInvescoFidelityExpense ratio0.40%0.08%1-yr return (as of Feb. 3, 2026)7.01%8.34%Dividend yield2.82%2.34%AUM$232 million$1.3 billionBeta (5Y monthly)0.520.55Beta measures price volatility relative to the S&P 500. The 1-yr return represents total return over the trailing 12 months.

FSTA is considerably more affordable than RSPS, with an expense ratio of just 0.08% versus 0.40%. In other words, investors can expect to pay $8 per year in fees for every $10,000 invested in FSTA compared to $40 per year with RSPS. Also, while the funds offer similar dividend yields, RSPS has a slight edge over FSTA.

Performance & risk comparisonMetricRSPSFSTAMax drawdown (5 y)-18.61%-16.57%Growth of $1,000 over 5 years$1,067$1,385What's insideFSTA holds 96 stocks and tracks mostly consumer defensive names (98%), with minor allocations to consumer cyclical. Its top positions are concentrated: Costco Wholesale, Walmart, and Procter & Gamble account for nearly 37% of assets. The fund is designed to mirror the broader consumer staples sector, but its largest holdings dominate overall exposure.

RSPS, by contrast, equally weights its 36 holdings from the S&P 500’s consumer staples sector. This offers a more balanced approach, as all of its holdings make up roughly 3% of assets.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsFSTA and RSPS each take different approaches to the consumer staples industry, and the right choice for your portfolio will depend on your investing preferences and risk tolerance.

FSTA is dominated by large brands, with household names accounting for a sizable share of assets. This can be an advantage when those particular companies are thriving, but if they falter, it could hit this ETF harder.

RSPS, on the other hand, is an equal-weight fund. While it holds far fewer stocks than FSTA (just 36 compared to 96), each of those stocks makes up roughly the same proportion of the portfolio. This can help reduce volatility, as all stocks are on equal footing and less likely to sway the fund’s overall performance.

There isn’t necessarily a clear winner between the two ETFs, as they offer unique angles that could appeal to different investors.

FSTA has the potential to outperform if its top holdings surge, but it could also be at risk of greater short-term volatility. RSPS’s equal-weight approach helps lower single-stock risk, but its smaller portfolio and reduced exposure to heavy-hitting companies could also limit its earning potential.

He now supports the merger, which would add to media competition.

Whether it's growth stocks with high potential or a broader basket of international stocks, IEMG and IXUS both offer different approaches to international stock exposure.

Both the iShares Core MSCI Emerging Markets ETF (IEMG +2.50%) and iShares Core MSCI Total International Stock ETF (IXUS +2.31%) offer exposure to non-U.S. equities, but IEMG targets only emerging markets, while IXUS covers developed and emerging markets globally. This comparison examines their costs, returns, risk, portfolio composition, and liquidity, helping investors see where the funds differ.

Snapshot (cost & size)MetricIXUSIEMGIssuerISharesISharesExpense ratio0.07%0.09%1-yr return (as of Feb. 7, 2026)31.67%37.83%Dividend yield3.01%2.51%AUM$54.40 billion$137.65 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year weekly returns. The 1-yr return represents total return over the trailing 12 months.

IEMG has a slightly higher expense ratio and lower return than IXUS, but its higher dividend yield may make the fund more appealing to income-driven investors.

Performance & risk comparisonMetricIXUSIEMGMax drawdown (5 y)(30.05%)(37.16%)Growth of $1,000 over 5 years$1,282$1,073What's insideIEMG holds 2707 emerging-market stocks, with its primary focus on the tech sector (23%), followed by financials (16%) and industrials (12%). Its top holdings are Taiwan Semiconductor Manufacturing (2330.SR), Samsung Electronics Ltd (005930.KS), and Tencent Holdings Ltd (0700.HK), giving it more exposure to Asian tech giants.

IXUS tracks an MSCI index covering large-, mid-, and small-cap stocks from developed and emerging markets, excluding the United States. It holds 4,211 securities, with its largest positions in Taiwan Semiconductor Manufacturing (2330.SR), Samsung Electronics Ltd (005930.KS), and ASML Holding N.V. (AMS:ASML.AS). Financial services (22%), industrials (15%), and technology (12%) are the top sectors by weight. The fund launched over 13 years ago, aiming for broad, low-cost international diversification.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsWith IEMG’s focus on the emerging market, it aims to maximize growth for holders. However, when looking at IXUS’ top holdings, it’s nearly identical to IEMG’s, as both funds have four of the same companies in their top five holdings. They also have a strong allocation to Asian stocks, so they experience similar volatility that’s unique to countries within the continent.

Combine that with the fact that IXUS outperformed IEMG by more than 20% over the last five years, and IXUS has shown just as much substantial growth.

When taking a further step back, IXUS has delivered a price return that is over 35% higher since both BlackRock ETFs launched on Oct. 18, 2012. So overall, IXUS seems to have the edge over IEMG. However, if investors still want a stronger international tech focus, IEMG remains a formidable option, as it’s more concentrated in those types of companies.

New York, New York--(Newsfile Corp. - February 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Klarna Group plc (NYSE: KLAR) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with Klarna's September 2025 initial public offering (the "IPO"), of the important February 20, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Klarna securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Klarna class action, go to https://rosenlegal.com/submit-form/?case_id=48971 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Registration Statement contained false and/or misleading statements and/or failed to disclose that: (1) Defendants materially understated the risk that Klarna's loss reserves would materially go up within a few months of the IPO, which they either knew of or should have known of given the risk profile of many individuals agreeing to Klarna's buy now, pay later ("BNPL") loans; and (2); as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Klarna class action, go to https://rosenlegal.com/submit-form/?case_id=48971 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283018

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

People use DBS automated teller machines (ATMs) in Singapore March 31, 2022. REUTERS/Caroline Chia Purchase Licensing Rights, opens new tab

SummaryCompaniesQ4 net profit at S$2.26 bln vs S$2.55 bln estimateNet interest margin declined to 1.93% in Q4Wealth AUM hits new high of S$488 billion in Q4Announces higher 66 cent final ordinary dividendROE at 13.5% in Q4 vs 15.8% a year agoSINGAPORE, Feb 9 (Reuters) - Singapore's biggest bank DBS Group (DBSM.SI), opens new tab on Monday maintained expectation that net profit this year will dip slightly from 2025's, after posting a 10% drop in fourth-quarter earnings that was weighed down by a lower net interest margin.

DBS, which is also Southeast Asia's largest bank by assets, said October-December net profit dropped to S$2.26 billion ($1.78 billion) from S$2.52 billion a year earlier.

The Week in Breakingviews newsletter offers insights and ideas from Reuters' global financial commentary team. Sign up here.

That missed the mean estimate of nearly S$2.55 billion from two analysts, according to LSEG data.

For the period, overall group net interest margin, a key profitability gauge, stood at 1.93% as compared to 2.15% the previous year, with net interest income impacted by lower domestic rates. Return on equity declined to 13.5% from 15.8% a year ago.

The lender's wealth segment's assets under management meanwhile grew 19% in constant-currency terms to a new high of S$488 billion in the fourth quarter.

In slides accompanying the results, CEO Tan Su Shan said group net interest income in 2026 is expected to be "slightly below 2025 levels", assuming a Singapore overnight rate average (SORA) of around 1.25%, two Federal Reserve rate cuts and a stronger Singapore dollar.

Net profit for the year is similarly expected to come in lower than in 2025, Tan added.

According to the bank's financial statement, provisions for bad loans jumped 81% to S$415 million in the fourth quarter, mainly due to real-estate exposure, while DBS wrote back S$206 million in general allowances, including amounts previously set aside for that exposure.

The bank declared an ordinary dividend of S$0.66 per share and a capital return dividend of S$0.15 per share for the fourth quarter.

DBS is the first Singapore lender to start this earnings season. Smaller peers United Overseas Bank (UOBH.SI), opens new tab and Oversea-Chinese Banking Corp (OCBC.SI), opens new tab are due to announce their results on February 24 and 25, respectively.

($1 = 1.2707 Singapore dollars)

Reporting by Rae Wee and Yantoultra Ngui; Editing by Cynthia Osterman, Mark Porter and Stephen Coates

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Yantoultra Ngui is the Southeast Asia Deals Correspondent of Reuters in Singapore, covering M&A and capital market activities in a region that is fast emerging as one of the world’s biggest economies. He previously was a reporter at Bloomberg and The Wall Street Journal (WSJ). Notably, he was part of WSJ's team that covered the financial scandal at Malaysian state fund 1MDB, and that won SOPA Excellence in Breaking News award for the coverage of the assassination of Kim Jong Nam, the half-brother of North Korea's leader Kim Jong Un, in Malaysia in 2018. Yantoultra graduated with an MBA in Finance from Universiti Putra Malaysia (UPM) in 2010.

The cloud computing colossus is spending like mad to win the artificial intelligence (AI) race.

Shares of Amazon.com (AMZN 5.49%) tumbled 12% this past week, according to data from S&P Global Market Intelligence, after the e-commerce titan forecast a staggering $200 billion in capital expenditures for 2026.

Image source: Amazon.

Sales and profits are growing nicely Amazon's fourth-quarter results weren't the problem.

Revenue jumped 14% to $213 billion, while operating income leaped 18% to $25 billion. The gains were driven by broad-based growth across Amazon's retail, advertising, and cloud businesses.

Today's Change

(

-5.49

%) $

-12.22

Current Price

$

210.47

Yet capex is set to grow even faster Here's the statement from Amazon CEO Andy Jassy that spooked investors (emphasis added):

With such strong demand for our existing offerings and seminal opportunities like AI, chips, robotics, and low earth orbit satellites, we expect to invest about $200 billion in capital expenditures across Amazon in 2026.

The first part of what Jassy said is just fine. Amazon is enjoying booming demand for its artificial intelligence (AI) services, custom-designed semiconductor chips used by its cloud computing customers, warehouse automation tools, and its forthcoming space-based internet offerings.

However, Wall Street had expected Amazon to spend about $150 billion on its promising expansion initiatives. The extra $50 billion or so was a wee bit more than many investors were comfortable with, so they decided to sell their shares.

Joe Tenebruso has positions in Amazon. The Motley Fool has positions in and recommends Amazon. The Motley Fool has a disclosure policy.

A drone view of a pump jack and drilling rig south of Midland, Texas, U.S. June 11, 2025. REUTERS/Eli Hartman Purchase Licensing Rights, opens new tab

SINGAPORE, Feb 9 (Reuters) - Oil prices dropped more than 1% at Monday's open as concerns about a possible conflict in the Middle East between the U.S. and Iran eased after both countries finished a round of talks on Friday.

Brent crude futures fell 89 cents, or 1.31%, to $67.16 a barrel by 2309 GMT.

The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.

U.S. West Texas Intermediate crude was at $62.76 a barrel, down 79 cents, or 1.24%.

Iran's top diplomat said on Friday that nuclear talks with the U.S. mediated by Oman were off to a “good start” and set to continue, in remarks that could help allay concern that failure to reach a deal might nudge the Middle East closer to war.

Reporting by Florence Tan; Editing by Jamie Freed

Our Standards: The Thomson Reuters Trust Principles., opens new tab

IWO charges a higher expense ratio but offers a slightly greater dividend yield than MGK. MGK has delivered stronger five-year growth and shallower drawdowns, while IWO brings broader diversification across small-cap growth stocks.

New York, New York--(Newsfile Corp. - February 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025, both dates inclusive (the "Class Period"), of the important February 9, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Integer common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Integer class action, go to https://rosenlegal.com/submit-form/?case_id=49170 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 9, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Integer materially overstated its competitive position within the growing electrophysiology ("EP") manufacturing market; (2) despite Integer's claims of strong visibility into customer demand, Integer was experiencing a sustained deterioration in sales relating to two of its EP devices; (3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for its cardio and vascular ("C&V") segment; (4) as a result of the above, defendants' positive statements about Integer's business, and operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Integer class action, go to https://rosenlegal.com/submit-form/?case_id=49170 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283007

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

SHANGHAI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, has won the “AI-Powered Future Award” at a high-level industry forum hosted by Tencent Health, underscoring its pioneering efforts in the field of “AI + Chronic Disease Services” and its strong leadership in the digital transformation of the healthcare sector.

The award was presented at the “T-Inspire CIO Private Forum,” organized by Tencent Health to convene senior executives and technology leaders from across the life sciences, pharmaceutical manufacturing and healthcare technology sectors.

Fangzhou Wins Tencent Health “AI-Powered Future Award”

As one of China’s leading “AI-enabled chronic care” platforms, Fangzhou has positioned technology as a core growth driver. In 2025, the Company completed a strategic upgrade of its H2H (Hospital-to-Home) model into an “AI + H2H” smart healthcare ecosystem. The model is built on long-term, trust-based doctor–patient relationships, which the company views as a key differentiator in chronic disease management.

Alongside this upgrade, Fangzhou has expanded its MaaS (Medicine as a Service) framework, integrating its solid foundation of patient trust with robust service delivery capabilities, translating “patient-centric care” into actionable, closed-loop, and scalable chronic disease management solutions. By doing so, Fangzhou is spearheading the industry’s transition from traditional pharmaceutical distribution to an intelligent healthcare service system. This shift marks a qualitative leap for chronic disease care — evolving from a reactive, one-way response model into a proactive, interactive, and collaborative partnership between patients and healthcare providers.

The Company’s collaboration with Tencent Health has played a central role in this process. Fangzhou contributes deep domain knowledge and real-world insights from chronic care scenarios, while Tencent provides cloud computing, data and AI infrastructure. Together, the partners have established a closed loop from technology validation to large-scale deployment, offering a replicable blueprint for intelligent chronic care service.

Fangzhou said its AI-driven model has helped overcome traditional constraints of time and geography in healthcare delivery, expanding post-hospital care coverage while improving service efficiency through algorithm-driven workflows. These capabilities have supported sustained growth in user engagement and platform activity, reflecting strong user retention and long-term service value.

The award comes against the backdrop of the Company’s improved financial performance. The company recently issued a positive profit alert with forecasted 2025 revenue of RMB 3.5 billion to RMB 3.55 billion, representing ~30% year-on-year growth, highlighting the strong performance of its chronic care model.

Looking ahead, Fangzhou will continue to strengthen its MaaS system, deepen AI integration across chronic disease services, and broaden access to professional, technology-enabled care while reinforcing its position as a key player in the country’s healthcare digitization drive.

About Fangzhou Inc.
Fangzhou Inc. (HKEX: 06086) is China’s leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians (as of June 30, 2025). The Company specializes in delivering tailored medical care and AI-enabled precision medicine solutions. For more information, visit https://investors.jianke.com.

Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: [email protected]

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/87935ce9-eea5-456f-bb01-a06951749c93

Address poisoning attacks have become a persistent issue on Ethereum, and ironically, they have contributed to the recent record-breaking daily transaction counts. 

According to ScamSniffer, there has already been a victim of address poisoning this year, and that loss cost $12.25 million. It happened in January when the victim copied the wrong address from their transaction history, not noticing until it was too late. 

A similar story emerged in December when one user lost a whopping $50 million in the same way. That makes it two victims across two months with a total loss of $62 million. 

According to a ScamSniffer’s January report, signature phishing also went up, with a total of $6.27M stolen across 4,741 victims in January. The two cases involved a user losing $3.02M and another losing $1.08M and accounted for 65% of all phishing losses.

Why address poisoning attacks have become rampant in recent months Address poisoning is a kind of scam that depends heavily on social engineering, where attackers monitor the target’s transaction histories, create lookalike addresses, and then send tiny amounts of ETH, called dust transactions, effectively poisoning the target’s history. 

What follows is a waiting game until the victim makes a mistake. The most important part of the whole operation, the dust transactions, were too expensive on Ethereum, so those address poisoning attacks were never as common before now.

However, in late 2025, Ethereum’s Fusaka upgrade came through, and it improved scalability while reducing the transaction fees, causing gas costs to drop sharply. The upgrade has done many great things for the ecosystem, but it also made these low-value dust transactions economically viable for bad actors at scale for the first time. 

Address poisoning contributes to daily transaction record on Ethereum  As earlier stated, address poisoning attacks depend heavily on dust transactions that the attackers send to poison the target’s history. 

These dust transactions are a prerequisite to the attack itself and are often numerous, and they are set like traps. But not all of them catch prey. Nevertheless, these dust transfers count as real transactions on-chain, and they have been inflating Ethereum’s metrics. 

Ethereum daily transaction chart. Source: Etherscan After the Fusaka upgrade, the network saw massive surges in activity that lasted into 2026. Daily transactions hit all-time highs, and active/new addresses spiked dramatically. 

However, analysts and researchers have pointed out that a substantial portion of the surge is linked to mass address poisoning campaigns rather than organic adoption or usage.

The fact that the ETH price barely had a bullish reaction to all these new records further justifies talk of artificial inflation. However, the Ethereum maxis are not nitpicking over where the traffic is coming from. 

They have celebrated the new records, and the Fusaka upgrade has been widely hailed as a great implementation. Never mind that low-value spam transactions dominated the records or that many of the new active addresses received such qualification because they received tiny stablecoin transfers as their first activity.